A combination of fluticasone furoate (FF) and umeclidinium (UMEC) has been considered for development for the treatment of asthma.

The primary objectives were to investigate the plasma and urine pharmacokinetics of FF/UMEC in combination compared with FF and UMEC monotherapies.

The combined administration of FF and UMEC provided slightly lower or similar systemic exposure for each component compared with administration of either component as monotherapy.

This provides a rationale for utilizing clinical pharmacology data from previous studies of FF or UMEC for the development of FF/UMEC as a combination therapy.

Further development of FF/UMEC as combination therapy is warranted based on these findings.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by GlaxoSmithKline. Medical writing assistance for this study was provided by Afia Akram, PhD, and Natasha Thomas, PhD, of Fishawack Indicia Ltd, and funded by GlaxoSmithKline. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).